First-Line Market For Melanoma Not A Lock For Bristol Or Roche
Data on Bristol's recently approved Yervoy and Roche's recently submitted vemurafenib show remarkable advances for melanoma but also establish competing options for first-line therapy.
Data on Bristol's recently approved Yervoy and Roche's recently submitted vemurafenib show remarkable advances for melanoma but also establish competing options for first-line therapy.